搜索筛选:
搜索耗时3.8442秒,为你在为你在102,285,761篇论文里面共找到 6 篇相符的论文内容
发布年度:
Met-positive (Met+), locally advanced or metastatic non-small cell lung cancer (NSCLC) with epiderma
[会议论文] 作者：Yi-Long Wu,Keunchil Park,Lianzhe Xu,Peiqi Li,Andreas Johne,James Chih-Hsin Yang,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
...
Met-positive (Met+), locally advanced or metastatic non-small cell lung cancer (NSCLC) with epiderma
[会议论文] 作者：Yi-Long Wu,Keunchil Park,Lianzhe Xu,Peiqi Li,Andreas Johne,James Chih-Hsin Yang,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: A secondary mutation in the EGFR (ie, T790M) and amplification of the c-Met proto-oncogene are the main causes of resistance to EGFR tyrosine kinase inhibitors (eg, gefitinib) in EGFRm+ NSC...
Activity of the c-Met inhibitor tepotinib (MSC2156119J) in combination with gefitinib in Asian patie
[会议论文] 作者：Yi-long Wu,Keunchil Park,Dong-wan Kim,Ross a.Soo,Huiling Xiong,Cindy Li,Christian Ihling,James chih-hsin,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: c-Met abnormalities can cause resistance to EGFR TKIs in EGFR mutant NSCLC patients (pts).The highly selective c-Met inhibitor tepotinib (MSC2156...
Phase Ⅱ trial comparing tepotinib + gefitinib with cisplatin + pemetrexed in Asian patients with gef
[会议论文] 作者：Yilong Wu,Keunchil Park,Dongwan Kim,Ross a.Soo,Cindy Li,Huiling Xiong,Christian Ihling,James chih-hsin,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Background: The combination of the highly selective c-Met inhibitor tepotinib (MSC2156119J) + gefitinib was shown to be well tolerated and have antitumor activity possibly associated with c-Met-positi...
Activity of the c-Met inhibitor tepotinib (MSC2156119J) in combination with gefitinib in Asian patie
[会议论文] 作者：Yi-long Wu,Keunchil Park,Dong-wan Kim,Ross a.Soo,Cindy Li,Huiling Xiong,Christian Ihling,James chih-hsin,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: c-Met abnormalities can cause resistance to EGFR TKIs in EGFR mutant NSCLC patients (pts).The highly selective c-Met inhibitor tepotinib (MSC2156119J) had promising activity in a phase Ⅰ tr...
Efficacy, safety and predictive biomarker results from a randomized phase Ⅱ study comparing MPDL3280
[会议论文] 作者：Spira,Keunchil Park,Julien Mazières,Johan F.,
来源：2015年临床肿瘤学新进展学术研讨会 年份：2015
...
相关搜索：
